Longitudinal study of lung function development in a cohort of Indian medical students: interaction of respiratory allergy and smoking

This study was done to identify some factors that affect the growth and development of lung function during adolescence and early adulthood. Forced expiratory spirograms and peak expiratory flow rates were obtained in a cohort of normal young men (n = 63) over a period of 4 years, at intervals of approximately 2 years. Two factors that disturbed the normal pattern of lung function development in this group were smoking and respiratory allergy. Among the smokers and the allergics the decline in the forced expiratory volume expressed as a percentage of the forced vital capacity (FEV1%), the forced expiratory flow in the middle half of the forced vital capacity (FEF25-75%) and the FEF25-75% expressed as a ratio of the forced vital capacity (FEF/FVC) was more than double that among the normal subjects. The number of smokers and of allergics increased during the course of the study from 15 to 19 and from 16 to 23 respectively. There was a significant (P less than .01) interaction between smoking and the manifestation of respiratory allergy. Among nonsmokers, the number of allergic subjects increased from 12 to 13, while among smokers it increased from 4 to 10, during the four years.     

H2-receptor blockade and exercise-induced asthma.

While in vitro studies suggest that H2-receptor blockade enhances mediator release from bronchial mast cells and leads to bronchoconstriction, in vivo studies have given conflicting results. Eight asthmatic subjects were given cimetidine 800 mg and placebo double-blind on different days. Baseline values of forced expiratory volume in one second (FEV1) were obtained before an 8 min standardized exercise test using a bicycle ergometer. Subjects inhaled cold, dry air and exercise on cimetidine and placebo days was matched for ventilation and thermal load. FEV1 was measured immediately, 5, 10, 15, and 20 min after exercise. No significant differences were observed between mean baseline FEV1, immediate post exercise FEV1, or maximum percentage fall from baseline after exercise on cimetidine or placebo days. Cimetidine does not appear to effect lung function or bronchial responses to cold air exercise challenge.     

Lung function development in Indian men and women during late adolescence and early adulthood--a longitudinal study

Lung function development was studied in a cohort of Indian men (n = 31) and women (n = 36), over a period of four years during late adolescence and early adulthood. Forced expiratory spirograms and peak expiratory flow rates were recorded at intervals of approximately two years. All volumes and flow rates were higher in men, but volume adjusted flow rates were higher in women. Forced vital capacity (FVC) forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) were significantly higher in men even after standardizing for age, height and weight. Height and PEF increased significantly in men and women over the four years. Volumes showed a greater increase whereas flow rates and volume adjusted flow rates showed a greater decrease in men. The decline in the forced expiratory flow in the middle half of the FVC (FEF 25-75%) was significantly less in women. These results suggest that although lung size is greater in men, small airway dynamics may be better in young women.     

肺高分辨率CT马赛克样灌注与小气道功能指数的相关分析

目的探讨肺小气道病变时高分辨率CT（HRCT）所示马赛克样灌注与小气道功能指标的相关性。方法选择HRCT上显示马赛克样灌注病例80例,由3位放射诊断医师对马赛克样灌注与小气道功能指标的相关性进行分析。结果马赛克样灌注与FEF 25%呈负相关（r=-0.48,P〈0.05）,与FEV1、FEF50%无相关性（r值分别为-0.27和-0.19,P〉0.05）。而空气潴留的程度与FEF25%、FEV1呈负相关（r值分别为-0.62和-0.41,P〈0.05）,与FEF 50%无相关性（r=-0.29,P〉0.05）。结论马赛克样灌注作为小气道病变的主要征象,其与FEF 25%具有良好的相关性,而空气潴留作为小气道阻塞的直接后果,其程度与FEV1、FEF 25%具显著相关性,即使肺功能检查结果正常时,也可以辅助诊断临床可疑的小气道阻塞。     

Inhaled dopamine induces bronchodilatation in patients with bronchial asthma.

OBJECTIVE: To determine the probable bronchodilating effect of dopamine administered by inhalation route in patients with crisis of bronchial asthma and the effect of dopamine on bronchial motor tone. DESIGN AND METHOD: We have studied eighteen (18) patients with crisis of bronchial asthma, ten (10) subjects with bronchial hyperreactivity and ten (10) healthy subjects. Patients with other pulmonary or cardiac disease were excluded. All received by inhalation placebo (0.9% saline solution), dopamine at 0.5 microg/kg/min (controlled by heart rate and arterial pressure with a dynamap), and placebo. Respiratory parameters: forced vital capacity (FVC), forced expiratory volume at the first second (FEV1), forced maximal expiratory flow (FEFmax) and forced expiratory flow at the 50% of vital capacity (FEF50) were measured in each protocol period. Student's paired t test, Wilcoxon and Mann Whitney analysis were performed. RESULTS: After dopamine inhalation, there was an increase of FVC by 23% (p<0.001); an increase of FEV1 by 39% (p<0.0001); an increase of FEF50 by 33% (p<0.001) and an increase of FEFmax by 31% (p<0.001). There were no respiratory parameter changes in both, subjects with bronchial hyperreactivity and normal after dopamine inhalation. CONCLUSIONS: Inhaled dopamine induces bronchodilatation in patients with crisis of bronchial asthma. Inhaled dopamine neither alters basal bronchial tone in healthy subjects nor in subjects with bronchial hyperreactivity.     

布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的研究

目的研究布地奈德联合沙丁胺醇雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效。方法观察组22例慢性阻塞性肺疾病急性加重期患者吸入布地奈德混悬液和沙丁胺醇气雾剂治疗5天,与对照组20例吸入沙丁胺醇气雾剂治疗5天进行对比,观察第1秒用力呼气容积(FEV1)占预计值百分比(FEV1%)和FEV1与用力肺活量比值(FEV1/FVC),以及空腹血糖、电解质等变化情况。结果观察组治疗前后比较FEV1%与FEV1/FVC:FEV1%与FEV1/FVC均明显升高,差异有显著性意义(P<0.01);对照组治疗前后比较,FEV1%与FEV1/FVC均有明显上升(P<0.01),治疗组的改善情况优于对照组;两组空腹血糖、电解质未发生明显变化。结论沙丁胺醇联合布地奈德可降低气道阻力,改善肺通气功能,提高其抗炎活性,临床效果确切,吸入治疗不良反应小,给药方便,值得推广。     

运动康复在支气管哮喘儿童中的应用效果观察

目的 分析运动康复在支气管哮喘儿童中的应用效果.方法 130例支气管哮喘患儿,根据随机数字表法分为观察组与对照组,各65例.参照组采纳基础治疗,观察组在参照组基础上采纳运动康复治疗.比较两组治疗前后肺功能指标、儿童哮喘生存质量问卷(PAQLQ)评分、6个月内复发率.结果 治疗后,观察组第1秒用力呼气容积占预计值百分比(...     

布地奈德对哮喘急性发作且伴有感染患儿的临床疗效

目的:分析布地奈德对支气管哮喘急性发作且伴有感染患儿的疗效及对肺功能指标的影响。方法:将本院收治的96例支气管哮喘急性发作且伴有感染的患儿作为研究对象,随机分为对照组和观察组各48例,两组患儿均给予常规抗感染治疗,对照组给予地塞米松雾化吸入,观察组给予布地奈德雾化吸入,比较两组患儿临床疗效和治疗前、治疗后1周第1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%)、肺活量(VC)、用力肺活量(FVC)等肺功能指标的改善状况及不良反应的发生情况。结果:观察组治疗总有效率为95.83%,高于对照组的72.92%(P<0.05)。两组患儿治疗后1周肺功能指标FEV1、FEV1%、VC、FVC水平较治疗前均升高,且观察组各指标水平均显著高于对照组(P均<0.01)。观察组患儿不良反应发生率(4.17%)低于对照组(18.75%)(P<0.05)。结论:布地奈德联合常规抗感染对治疗支气管哮喘急性发作且伴有感染的患儿具有良好的临床疗效,可有效改善FEV1、FEV1%等肺功能指标,且不良反应发生率较低,具有较高的安全性,因此具有良好的临床应用价值。     

舌下脱敏治疗儿童过敏性支气管哮喘疗效观察

目的:探讨舌下特异性免疫治疗(SLIT)对于儿童过敏性支气管哮喘的疗效.方法:将72例儿童过敏性支气管哮喘患儿随机分成两组各36例,治疗组在吸入低剂量糖皮质激素(相当于200 μg布地奈德等效剂量)的基础上加用舌下含服粉尘螨滴剂治疗,对照组单纯吸入低剂量糖皮质激素,疗程均为18个月.观察两组在治疗期间人均累计哮喘急性发...     

盐酸西替利嗪滴剂联合丙酸氟替卡松吸入气雾剂治疗儿童过敏性鼻 炎合并支气管哮喘疗效观察

目的:观察盐酸西替利嗪滴剂联合丙酸氟替卡松吸入气雾剂治疗过敏性鼻炎(AR)合并支气管哮喘(BA)患儿的疗效及 安全性。方法:选取2020 年1 月-2022 年6 月我院收治的AR 合并BA 患儿84 例,按随机数表法分为联合组与对照组各42 例。 对照组给予丙酸氟替卡松吸入气雾剂吸入治疗,联合组则采用盐酸西替利嗪滴剂联合丙酸氟替卡松吸入气雾剂治疗,比较两组 患儿治疗前后AR 和BA 严重程度评分、肺功能指标[第1 秒用力呼气量(FEV1)、呼气流速(PEF)、用力肺活量(FVC)]、血清酶 学[可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管细胞间粘附分子-1(sVCAM-1)、白细胞介素-4(IL-4)、IL-10]、血清淀粉样 蛋白(SAA)水平及不良反应发生情况。结果:治疗后,联合组AR 与BA 严重程度评分低于对照组,FEV1、PEF 及FVC 水平高于 对照组(P 均<0. 05);两组sICAM-1、sVCAM-1、IL-4、IL-10 及SAA 水平均下降,且联合组均低于对照组( P 均<0. 05);两组患儿 不良反应发生率比较差异无统计学意义(P>0. 05)。结论:采用盐酸西替利嗪滴剂联合丙酸氟替卡松吸入气雾剂治疗AR 合并 BA 患儿,能显著减轻临床症状,有效改善肺功能,调节血清酶学指标与SAA 水平,且不会增加不良反应的发生。     

微创漏斗胸矫治术后早期心肺功能变化的研究

目的 了解胸腔镜下微创漏斗胸矫治术（Nuss手术）治疗漏斗胸术后早期患者心肺功能的变化.方法 2006年l2月-2009年7月,我院共有23例漏斗胸患者采用胸腔镜下Nuss手术进行矫治,其中13例大于9岁的漏斗胸患者行术前、术后3个月和术后1年的肺功能检测,包括肺活量（VC）、肺总量（TLC）、用力肺活量（FVC）、第1秒用力呼气容积（FEV1）和50%肺活量最大呼气流量（MEF50）.所有23例患者均行术前、术后3个月和术后1年的心功能检测,包括每搏量（SV）、心输出量（CO）和心脏指数（CI）.结果 术后3个月TLC、VC、FEV1、FVC均较术前下降,其中VC、FEV1、FVC下降明显[VC：（81.08±12.74）vs（92.15±11.36）;FEV1：（83.54±10.81）vs（93.62±10.76）;FVC：（85.92±10.59）vs（93.85±10.18）,P＜0.05],术后1年均可恢复到术前水平（P＞0.05）.MEF50术后3个月未见明显下降,术后1年较术前升高（P＞0.05）.术后3个月、术后1年每搏量和心输出量均较术前有显著提高（P＜0.05）;术后3个月、术后1年心脏指数均较术前有提高,其中术后3个月提高明显[（3.45±0.42）vs（3.15±0.42）,P＜0.05].结论 微创漏斗胸矫治术后患者早期肺功能虽有下降,但术后随访显示可恢复至术前水平,而术后早期患者的心功能较术前有提高.     

Cardiorespiratory responses to submaximal incremental exercise are not affected by one night's sleep deprivation during the follicular and luteal phases of the menstrual cycle

The purpose of the study was to investigate the effects of one night's sleep deprivation on the cardiorespiratory responses to exercise during the follicular and luteal phases of the menstrual cycle. We have studied nine, healthy females aged 24-35 years with regular menstrual cycles. Each subject performed spirometric tests at rest and then an incremental exercise testing during 11-13 days of follicular phase and 22-24 days of luteal phase following one normal night's sleep or one night's sleep loss. Compared with resting values exercise produced significant increases in cardiorespiratory variables including oxygen uptake (VO2), carbon dioxide production (VCO2), tidal volume (VT), respiratory rate (RR), minute ventilation (VE), systolic blood pressure, heart rate (HR) and respiratory quotient (R). However, it did not alter significantly diastolic blood pressure, end-tidal PO2 (PETO2), end-tidal PCO2 (PETCO2) and arterial oxygen saturation (SaO2). Spirometric variables which include forced vital capacity (FVC), forced expiratory volume in one s (FEV1), FEV1/FVC%, forced expiratory volume in three s (FEV3), forced expired flow from 25-75% of FVC (FEF 25-75%), forced expired flow at 25% of FVC (FEF 25%), forced expired flow at 50% of FVC (FEF 50%), forced expired flow at 75% of FVC (FEF 75%), forced expired flow from 75-85% of FVC (FEF 75-85%), peak expiratory flow (PEF), expiratory reserve volume (ERV), inspiratory capacity (IC) and maximal voluntary ventilation (MVV) and cardiorespiratory variables were not different between the cycle phases after one normal night's sleep or one night's sleep deprivation. Neither menstrual cycle phase nor sleep deprivation affected spirometric and cardiorespiratory parameters. We suggest that one night's sleep deprivation does not produce alterations in spirometric parameters and cardiorespiratory responses to submaximal incremental exercise during the follicular and luteal phases.     

辛芩雾化剂对支气管哮喘患者肺功能及其生命质量的影响

目的 探讨辛芩雾化剂对支气管哮喘患者肺功能及其生命质量的影响.方法 124例支气管哮喘患者按随机数字表随机分为对照组(60例)和观察组(64例).2组均予同时配合抗炎、抗过敏、止咳、化痰等对症治疗.在此基础上,观察组加用辛芩雾化剂(3级:辛芩雾化剂30 ml;2级:辛芩雾化剂15 ml;1级:辛芩雾化剂15 ml)超声雾化吸入,对照组加用丙酸倍氯米松气雾剂(3级:200～300 μg;2级:100～200μg;1级:100～200 μg)吸入,2组中2、3级患者均加用β2受体激动剂吸入,于治疗3个月后评估临床症状、征候积分、疗效及生命质量评分.结果 观察组和对照组总有效率比较,差异无统计学意义[96.9％ (62/64)比100.0％ (60/60)] (P ＞0.05);观察组和对照组治疗后3个月测得的第1秒用力呼气容积占预计值百分比(FEV1％)、最大呼气流量(PEF)、最大呼气流速(PEFR)值均较治疗前明显改善[观察组:FEV1％为(87±4)％比(70±4)％,PEF为(350±40) L/min比(316±35) L/min,PEFR为(13.4±2.4)％比(18.3±3.0)％;对照组:FEV1％为(86±4)％比(71±4)％,PEF为(346±37) L/min比(326±37) L/min,PEFR为(14.3±2.1)％比(19.7±2.9)％](均P＜0.05).但2组治疗后3个月测得的FEV1％、PEF、PEFR值比较差异无统计学意义(P＞0.05).观察组生命质量评分总分[(62±6)分]明显优于对照组[(82±7)分](P＜0.05).结论 辛芩雾化剂吸入替代激素治疗能改善支气管哮喘患者肺功能及其生命质量,其治疗成人支气管哮喘安全、有效.     

多索茶碱和茶碱缓释片对支气管哮喘的疗效和安全性比较

目的 比较多索茶碱和茶碱缓释片对稳定期哮喘患者的疗效和安全性,为临床用药提供依据。方法 前瞻性入组汉中市中心医院收治的稳定期哮喘患者100例,随机分为观察组（n=50）和对照组（n=50）。观察组给予多索茶碱400 mg,2次/d;对照组给予300 mg茶碱缓释片,2次/d。两组疗程均为6周。观察记录两组患者治疗前后的肺功能指标-1秒用力呼气量（FEV1）,用力肺活量（FVC）,FEV1/FVC（%）,最大呼气流量（PEFR）及不良反应。结果 治疗前,两组患者肺功能指标（FEV1、FVC、FEV1/FVC、PEFR）均无统计学差异;治疗6周后,与治疗前比较,两组患者肺功能FEV1、FEV1/FVC、PEFR均显著提高,但观察组和对照组患者肺功能比较没有统计学差异。对照组患者总不良反应事件发生率显著高于观察组（P<0.05）。结论 茶碱缓释片和多索茶碱均能改善轻度支气管哮喘患者肺功能,但多索茶碱安全性好于茶碱缓释片。     

A simple exercise test in assessment of asthma

Exercise-induced asthma (EIA) is a manifestation of the bronchial hyper-responsiveness of asthmatic patients. Laboratory methods for measuring EIA are now well standardised. We compared a stepping test with a standard treadmill exercise test to determine whether the sensitivity of the latter could be maintained with the simplified test. We used heart rate as a measure of exercise intensity and changes in forced expiratory volume in 1 second (FEV1) to record bronchial responsiveness. In 32 adolescent asthmatic patients we demonstrated a fall in FEV1 of 10% or more in 27 following the treadmill test and in 25 following the stepping test. There was a strong correlation between the maximum falls of FEV1 following the two exercise challenges (r = 0.92 p less than 0.0001). There was poor agreement between the patient's history of EIA and the demonstration of a 10% fall of FEV1 after exercise in 11 patients. Notably all six patients who claimed no association of exercise with their asthma symptoms clearly demonstrated a fall in FEV1 of 10% or more following the treadmill challenge. We conclude that a simplified exercise test can be both objective and sensitive in detecting EIA and therefore useful in the assessment of the asthmatic patient and the effect of therapy.     

Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects.

1. The effects of pretreatment with clonidine and rilmenidine, a new alpha 2-adrenoceptor agonist, on the bronchial responses to inhaled histamine were studied on 3 different days in a controlled, double-blind, randomized study in 12 asymptomatic asthmatic subjects. Clonidine and rilmenidine were orally administered as single and equipotent doses of 150 micrograms and 1 mg, respectively. All the subjects were non-smokers with normal lung function tests (forced expiratory volume in one second (FEV1) = 97 +/- 10% predicted FEV1). 2. Histamine (first dose = 543 nmol) was delivered by a breath activated dosimeter (DeVilbiss no. 646 nebulizer) every 5 min; FEV1 was measured in triplicate after each dose and the largest value was analyse. The three dose-response curves were compared by analysis of variance. 3. Both clonidine and rilmenidine decreased arterial blood pressure in all subjects. There was no difference in baseline values and pre-challenge values of FEV1 after placebo, clonidine and rilmenidine on the 3 study days. Compared with placebo, both rilmenidine and clonidine significantly increased the bronchial responses to histamine (P less than 0.05 and P less than 0.01 respectively) an effect which was significantly more marked with clonidine than rilmenidine (P less than 0.05). 4. We suggest that the enhancement of bronchial responsiveness to histamine by clonidine and rilmenidine may result from their effects on both central and peripheral alpha 2-adrenoceptors, and that the lesser aggravation of histamine-induced bronchial obstruction in asthmatic subjects on rilmenidine might be explained by its lesser central and/or greater peripheral effects than clonidine.     

孟鲁司特改善支气管哮喘患者肺功能和气道炎症的临床研究

目的:探讨孟鲁司特对支气管哮喘患者肺功能和气道炎症的临床疗效。方法:选取我院收治的支气管哮喘患者96例,随机分为治疗组与对照组,每组48例,对照组采用吸氧、解痉、抗感染及抗炎等常规治疗,治疗组在对照组的基础上加用孟鲁司特(10mg·d-1)治疗。比较2组治疗前、后肺功能指标用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、用力呼气流量(PEFR),气道炎症指标血白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的变化。结果:治疗10周后,治疗组的FEV1、PEFR、IL-6、TNF-α显著优于对照组(P<0.01或P<0.05)。2组FVC差异无统计学意义(P>0.05)。结论:孟鲁司特对支气管哮喘患者肺功能和气道炎症的改善有较好的疗效,值得临床推广。     

金荞麦胶囊联合沙美特罗替卡松吸入粉雾剂治疗儿童支气管哮喘临床疗效研究

目的探讨金荞麦胶囊联合沙美特罗替卡松吸入粉雾剂治疗儿童支气管哮喘的疗效及对炎性因子、免疫功能的影响。方法选取海南省海口市琼山区妇幼保健院2018年1月至2020年1月收治的支气管哮喘患儿60例,按随机数字表法分为对照组和观察组,各30例。两组均给予沙美特罗替卡松吸入粉雾剂治疗,观察组加用金荞麦胶囊。两组均以1个月为1个疗程,共治疗3个疗程。结果观察组患儿总有效率为90.00%,显著高于对照组的63.33%(P<0.05);治疗后,观察组患儿第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC均显著高于对照组(P<0.05);观察组患儿的血清白细胞介素4、白细胞介素6、抗肿瘤坏死因子-α水平均显著低于对照组(P<0.05);观察组患儿的免疫指标(免疫球蛋白G、免疫球蛋白M、免疫球蛋白A)水平均显著高于对照组(P<0.05);观察组和对照组不良反应发生率相当(6.67%比16.67%,P>0.05)。结论金荞麦胶囊联合沙美特罗替卡松吸入粉雾剂治疗儿童支气管哮喘疗效良好,可有效缓解临床症状,改善肺功能和免疫功能,调节血清炎性因子水平,且安全性较好。     

Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance

Preliminary feedback from physicians and pharmacists in Trinidad suggests that generic pressurized metered dose inhalers (pMDIs) of salbutamol are not as effective as Ventolin and that they have poor patient acceptance. This study was designed to compare the clinical efficacy and tolerance of two generic inhalers available in Trinidad (Asthalin and Salomol) with Ventolin in stable asthmatics. Twenty-one physician-diagnosed stable asthmatics were administered the inhalers in a Latin-square randomized double-blind study with 80% power to identify differences in forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC) and peak expiratory flow rate (PEFR) before and 0.25, 0.5, 1, 2 and 3 h after inhalation. Pulse and blood pressure were recorded at similar time points. Seventeen patients completed the study. Within 15 min basal respiratory function significantly increased following inhalation from all three inhalers with a gradual decline over the observation period. Asthalin produced the highest changes in FEV1, PEFR and the longest duration of effect (p < 0.001). Respiratory function tests did not differ between Ventolin and Salomol. Pulse was not affected by treatments and mean arterial blood pressure fell after Asthalin. Ventolin was not superior to the generic pMDIs in improving pulmonary function. Fifteen patents reported cough sensation after Asthalin. Throat irritation and cough sensation after inhaling Asthalin may negate patient compliance. We suggest that optimizing particle size and cascade impact in the Asthalin inhaler may improve patient tolerance and acceptance with enhanced treatment outcome with cost-efficacy.     

呼吸功能锻炼在胸廓畸形患者术后康复中的应用效果观察

目的研究呼吸功能锻炼对胸廓畸形患者术后康复效果的影响。方法73例胸廓畸形矫治术后患者,随机分为对照组(37例)及观察组(36例)。对照组患者按照一般术后常规方法进行护理,观察组患者在对照组的基础上进行呼吸功能锻炼。比较两组患者术前、术后7 d肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)]、动脉血气分析指标[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)]水平;住院时间以及肺部感染发生情况。结果术前,两组患者的FVC、FEV1、PaO2、PaCO2水平比较,差异均无统计学意义(P>0.05);术后7 d,观察组患者的FVC、FEV1、PaO2水平高于对照组,PaCO2水平低于对照组,差异均具有统计学意义(P<0.05)。观察组肺部感染发生率2.78%低于对照组的18.92%,住院时间(10.08±2.54)d短于对照组的(11.59±3.47)d,差异均具有统计学意义(P<0.05)。结论胸廓畸形患者术后进行呼吸功能锻炼可使其肺功能得到改善,减少肺部感染的发生,加快患者康复出院速度。